No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 100
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
200 (estimated)
Sponsor
Timothy Mullett · Other
Who this trial is looking for
This trial is looking for members of state teams working on lung cancer screening in Mississippi and Nevada. Participants will help improve the screening process and are expected to take part in assessments and activities related to the study.
Are You a Good Fit for This Trial?
You may be able to join if
I am a member of a lung cancer screening team in Mississippi or Nevada.
I hold a leadership position on the Mississippi or Nevada state team.
I am an active member of the Mississippi Lung Cancer Roundtable or Nevada Lung Cancer Coalition.
I am willing to participate in study-related assessments and activities.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to re…
This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to reduce lung cancer-related death in underserved communities. Previous research had success with implementing interventions in Kentucky which has lead to significant increases in lung cancer screening rates and a rapid decline in late-stage lung cancer diagnoses within the state. The goal is to offer the opportunity to replicate this work in states which are eager to address suboptimal screening rates, high lung cancer-related death, and significant health equity concerns. The QUILS™ SBI intervention involves translating the success of the initial work in Kentucky to impact lung cancer screening implementation and lung cancer outcomes in MS and NV through close collaboration with state-based partners. The QUILS™ SBI intervention may be an effective way to improve the statewide capacity for implementing and sustaining lung cancer screening in MS and NV.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Member of a state-based lung cancer screening implementation team in Mississippi or Nevada.
* Leadership member of the Mississippi state team or Nevada state team
* Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC)
* Willin…
Inclusion Criteria:
* Member of a state-based lung cancer screening implementation team in Mississippi or Nevada.
* Leadership member of the Mississippi state team or Nevada state team
* Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC)
* Willing to participate in study-related assessments an implementation activities
Exclusion Criteria:
* None
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.